<DOC>
	<DOCNO>NCT00001765</DOCNO>
	<brief_summary>This study investigate safety effectiveness modify stem cell transplant procedure treat chronic granulomatous disease ( CGD ) patient active infection . CGD inherit disorder neutrophils-a type infection-fighting white blood cell-that leave patient vulnerable life-threatening infection . Transplantation donate stem cell ( cell produce bone marrow mature different blood components-white cell , red cell platelet ) cure CGD . However , procedure carry significant risk death , particularly patient active infection , require completely suppress immune system high-dose chemotherapy radiation . In addition , lymphocytes-another type infection-fighting white blood cell-from donor may cause call graft vs. host disease ( GvHD ) , donor cell recognize patient 's cell foreign mount immune response destroy . To try reduce risk , patient study give low-dose chemotherapy radiation , regimen easy body tolerate involve short period complete immune suppression . Also , donor 's lymphocyte remove rest stem cell transplant , reduce risk GvHD . Patients CGD age age 1 55 year old active infection family member well match donor may eligible study . Candidates medical history , physical examination blood test , lung heart function test , X-rays chest sinus , dental eye examination . A bone marrow sample may take evaluate disease status . This test , do local anesthetic , use special needle draw bone marrow hipbone . Stem cell collect patient donor . To , hormone G-CSF injected skin several day increase stem cell production . Then , stem cell collect apheresis . In procedure blood drawn needle place one arm , pump machine desire cell separate remove , rest blood return needle arm . A large plastic tube ( central venous line ) place major vein . It stay body used entire treatment period deliver donate stem cell , give chemotherapy medication , include antibiotic blood transfusion , need , withdraw blood sample . Several day transplant procedure , patient start low-dose chemotherapy cyclophosphamide fludarabine , two commonly use anti-cancer drug . They also give anti-thymocyte globulin prevent rejection donate cell . When condition therapy complete , stem cell infused central line . Patients give cyclosporine mouth vein 4 day 3 month stem cell transplant help prevent rejection . The average hospital stay stem cell transplant 30 day . After discharge , patient return follow-up clinic visit weekly twice weekly 4 month . These visit include symptom check , physical examination , blood test . Blood transfusion give need . Subsequent visit schedule 4 , 6 , 12 , 18 , 24 , 30 36 month transplant often require , yearly .</brief_summary>
	<brief_title>Stem Cell Transplant Following Low-Intensity Chemotherapy Treat Chronic Granulomatous Disease</brief_title>
	<detailed_description>Chronic Granulomatous Disease ( CGD ) inherit disorder neutrophil function . Patients profoundly immunocompromised , plague early life recurrent , life threaten infection . Allogeneic stem cell transplantation cure CGD . The goal phase I/II study investigate safety efficacy novel approach allogeneic stem cell transplantation aim decrease transplant relate morbidity mortality . We treat patient CGD allogeneic , G-CSF mobilize peripheral blood stem cell transplant HLA identical family member . The graft T-cell deplete decrease incidence acute graft vs. host disease . Donor T-cells infuse post-transplant engraftment donor stem cell unsatisfactory . The preparative regimen utilized provide intense immunosuppression without myeloablation . It design allow donor stem cell engraftment minimize serious transplant relate toxicity . The end point study engraftment , degree donor-host chimerism , incidence acute chronic GVHD , transplant relate morbidity mortality well overall survival .</detailed_description>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>INCLUSION CRITERIA : PATIENT CRITERIA : Ages 1 55 year DHR proven Chronic Granulomatous Disease : Includes gp91phox , p47phox , p22phox p67phox deficiency . Free active infection . Patient experience 2 prior infection require treatment intravenous antibacterial antifungal therapy . HIV negative . No major organ dysfunction preclude transplantation . HLA identical sibling parent compatible 6 HLA A , B , DR antigens serotyping DNA type technique . Left ventricular ejection fraction : great 40 % predict . ECOG performance status 0 1 . DONOR CRITERIA : HLA identical sibling donor parent donor . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke , history severe heart disease ) . Female xlinked CGD carrier must great 30 % normal neutrophil . EXCLUSION CRITERIA : Patient donor pregnant . Age great 55 year . ECOG performance status 2 . Evidence rapid deterioration due progressive infection and/or organ damage . Left ventricular ejection fraction : great equal 35 percent predict . Creatinine Clearance great equal 50 . Serum bilirubin great equal 4 mg/dl , transaminases great equal 3x upper limit normal . HIV negative . Donors positive HBV , HCV HTLV use discretion investigator . Malignant disease liable relapse progress within 5 year . Donors unfit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history stroke , history heart disease , thrombocytopenia . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Engraftment</keyword>
	<keyword>Minitransplant</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Neutrophil</keyword>
	<keyword>Allogenic</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Anti-Thymocyte Globin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Nonmyeloablative Bone Marrow Transplantation</keyword>
	<keyword>Graft-versus-host Disease</keyword>
	<keyword>Chronic Granulomatous Disease</keyword>
</DOC>